ICD-10 E10.A2 is officially defined as "Type 1 diabetes mellitus, presymptomatic, Stage 2." code E10.A2 is referenced in 4 tracked payer policy changes from Independence Blue Cross and Healthfirst. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code E10.A2 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Independence Blue Cross expanded coverage of teplizumab-mzwv (Tzield) effective 12/07/2026 to include pediatric individuals ages 1 to <8 years with stage 2 type 1 diabetes. Simultaneously, the policy clarified that use in ages 8-17 with stage 3 T1D remains experimental/investigational and not covered. Six ICD-10 diagnosis codes (R73.01, R73.02, R73.03, R73.09, R76.0, Z83.3) were removed from the policy.
Independence Blue Cross expanded coverage for Teplizumab-mzwv (Tzield) to include pediatric patients aged 1 to <8 years with stage 2 type 1 diabetes, while maintaining non-coverage for patients aged 8-17 with stage 3 T1D (classified as experimental/investigational). Six ICD-10 diagnosis codes were removed from the policy. Billing teams must update systems to reflect the new pediatric age coverage expansion effective December 7, 2026.
This is a reissue with no substantive changes to the Tzield (teplizumab-mzwv) coverage policy. The policy was previously updated on 11/18/2024 to remove medical necessity criteria based on family history of type 1 diabetes; this 05/28/2025 reissue confirms those changes under the annual review process. Coverage remains limited to stage 2 type 1 diabetes in patients 8+ years old who meet specific autoantibody and glucose tolerance criteria, prescribed by an endocrinologist, with one lifetime treatment course of 14 doses.
Healthfirst's October 2026 tip sheet on diabetes mellitus documentation and ICD-10-CM coding explains how to document and code diabetes, including linking complications with the 'diabetic' descriptor, documenting insulin use with its regimen in the final assessment, and avoiding terms such as 'history of' for a current condition. It is educational only, and Healthfirst states that it does not guarantee coverage or payment, which depend on the member's evidence of coverage and the provider's participation agreement.
Watch E10.A2
Get one email when a payer policy names E10.A2, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.